Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma

Journal of Endocrinology

Volumn 190, Issue 2, 2006, Pages 271-285

  Manhès, Caroline ^a,b   Kayser, Christine ^a,b   Bertheau, Philippe ^a,c   Kelder, Bruce ^d   Kopchick, John J ^d   Kelly, Paul A ^a,b   Touraine, Philippe ^a,e   Goffin, Vincent ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d OHIO UNIVERSITY   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MILK PROTEIN; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST DEVELOPMENT; BREAST PAPILLOMA; BREAST TUMOR; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; LACTATION; LACTATION DISORDER; MAMMARY GLAND FUNCTION; METAPLASIA; MILK PRODUCTION; MORPHOLOGY; MOUSE; MULTIPARA; NONHUMAN; NULLIPARA; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; TISSUE HOMOGENATE; TRANSGENE;

ANIMALS; AUTOCRINE COMMUNICATION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LACTATION; LIPID METABOLISM; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; METAPLASIA; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MILK; MILK PROTEINS; PAPILLOMA; PREGNANCY; PROLACTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 33747881292     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06829     Document Type: Article

References (52)

1. Abell K, Bilancio A, Clarkson RW, Tiffen PG, Altaparmakov AI, Burden TG, Asano T, Vanhaesebroeck B & Watson CJ 2005 Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nature Cell Biology 7 392-398.
2. Bernichtein S, Jomain JB, Kelly PA & Goffin V 2003a The N-terminus of human prolactin modulates its biological properties. Molecular and Cellular Endocrinology 208 11-21.
3. Bernichtein S, Kayser C, Dillner K, Moulin S. Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA & Goffin V 2003b Development of pure prolactin receptor antagonists. Journal of Biological Chemistry 278 35988-35999.
4. Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo MM, Cardiff RD, Miyoshi K, Wagner KU et al. 2003 Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22 3875-3887.
5. Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL, Weinberg RA, Kelly PA & Ormandy CJ 1999 Prolactin controls mammary gland development via direct and indirect mechanisms. Developmental Biology 210 96-106.
6. Clevenger CV, Chang WP, Ngo W, Pasha TM, Montone KT & TomaszewskiJE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. American Journal of Pathology 146 695-705.
7. Clevenger CV, Furth PA, Hankinson SE & Schuler LA 2003 The role of prolactin in mammary carcinoma. Endocrine Reviews 24 1-27.
8. Collares-Buzato CB, Leite AR & Boschero AC 2001 Modulation of gap and adherens junctional proteins in cultured neonatal pancreatic islets. Pancreas 23 177-185.
9. Courtillot C, Binart N, Plu-Bureau G, Goffin V, Kuttenn F, Kelly PA & Touraine P 2006 Benign breast diseases. Journal of Mammary Gland Biology and Neoplasia (in press).
10. Das R & Vonderhaar BK 1997 Prolactin as a mitogen in mammary cells. Journal of Mammary Gland Biology and Neoplasia 2 29-39.
11. Edwards GM, Wilford FH, Liu X, Hennighausen L, Djiane J & Streuli CH 1998 Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. Journal of Biological Chemistry 273 9495-9500.
12. Ginsburg E & Vonderhaar BK 1995 Prolactin synthesis and secretion by human breast cancer cells. Cancer Research 55 2591-2595.
13. Goffin V, Bernichtein S, Touraine P & Kelly PA 2005 Development and potential clinical uses of human prolactin receptor antagonists. Endocrine Reviews 26 400-422.
14. Gourdou I, Paly J, Hue-Beauvais C, Pessemesse L, Clark J & Djiane J 2004 Expression by transgenesis of a constitutively active mutant form of the prolactin receptor induces premature abnormal development of the mouse mammary gland and lactation failure. Biology of Reproduction 70 718-728.
15. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B & Speizer FE 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 91 629-634.
16. Hennighausen L & Robinson GW 1998 Think globally, act locally: the making of a mouse mammary gland. Genes and Development 12 449-455.
17. Hennighausen L & Robinson GW 2001 Signaling pathways in mammary gland development. Annual Review of Cell and Developmental Biology 1 467-475.
18. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E & Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO Journal 16 6926-6935.
19. Jackson TA, Koterwas DM, Morgan MA & Bradford AP 2003 Fibroblast growth factors regulate prolactin transcription via an atypical Rac-dependent signaling pathway. Journal of Molecular Endocrinology 17 1921-1930.
20. Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick JJ & Binart N 2002 The role of prolactin and growth hormone in mammary gland development. Molecular and Cellular Endocrinology 197 127-131.
21. Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J & Wennbo H 2003 Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144 2269-2278.
22. Leung K, Nagy A, Gonzalez-Gomez I, Groffen J, Heisterkamp, N & Kaartinen V 2003 Targeted expression of activated Rac3 in mammary epithelium leads to defective postlactational involution and benign mammary gland lesions. Cells Tissues Organs 175 72-83.
23. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Predow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM & Nevalainen MT 2004 Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Research 64 4774-4782.
24. Liu X, Robinson GW & Hennighausen L 1996 Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Journal of Molecular Endocrinology 10 1496-1506.
25. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA & Goffin V 2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19 4695-4705.
26. Medina D 2005 Mammary development fate and breast cancer risk. Endocrine-Related Cancer 12 483-495.
27. McGrane MM, de Vente J, Yuri J, Bloom J, Park E, Wynshaw-Boris A, Wagner T, Rottman FM & Hanson RW 1988 Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice. Journal of Biological Chemistry 263 11443-11451.
28. Miller SL, DeMaria JE, Freier DO, Riegel AM & Clevenger CV 2005 Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Journal of Molecular Endocrinology 19 939-949.
29. Miyoshi K, Shillingford JM, Le Provost F, Gounari F, Bronson R, von Boehmer H, Taketo MM, Cardiff RD, Hennighausen L & Khazaie K 2002 Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. PNAS 99 219-224.
30. Muller T, Bain G, Wang X & Papkoff J 2002 Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. Experimental Cell Research 280 119-133.
31. Naylor MJ, Lockefeer JA, Horseman ND & Ormandy CJ 2003 Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 20 111-114.
32. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM & Harkonen PL 1997 Prolactin and prolactin receptors are expressed and functioning in human prostate. Journal of Clinical Investigation 99 618-627.
33. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ & Ali S 2006 Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Research 66 1824-1832.
34. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas BK, Buteau H, Edery M, Brousse N, Babinet C, Binart N et al. 1997 Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes and Development 11 167-178.
35. Ormandy CJ, Horseman ND, Naylor MJ, Harris J, Robertson F, Binart N & Kelly PA 2001 Mammary gland development. In Prolactin, pp 219-232. Ed ND Horseman. Boston, MA, USA: Kluwer Academic Press.
36. Pittius CW, Hennighausen L, Lee E, Westphal H, Nicols E, Vitale J & Gordon K 1988a A milk protein gene promoter directs the expression of human tissue plasminogen activator cDNA to the mammary gland in transgenic mice. PNAS 85 5874-5878.
37. Pittius CW, Sankaran L, Topper YJ & Hennighausen L 1988b Comparison of the regulation of the whey acidic protein gene with that of a hybrid gene containing the whey acidic protein gene promoter in transgenic mice. Journal of Molecular Endocrinology 2 1027-1032.
38. Prieto PA, Mukerji P, Kelder B, Erney R, Gonzalez D, Yun JS, Smith DF, Moremen KW, Nardelli C & Pierce M 1995 Remodeling of mouse milk glycoconjugates by transgenic expression of a human glycosyltransferase. Journal of Biological Chemistry 270 29515-29519.
39. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP & Schuler LA 2003 Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22 4664-4674.
40. Russo IH & Russo J 1988 Hormone prevention of mammary carcinogenesis: a new approach in anticancer research. Anticancer Research 8 1247-1264.
41. Santen RJ & Mansel R 2005 Benign breast disorders. New England Journal of Medicine 353 275-285.
42. Schwertfeger KL, Richert MM & Anderson SM 2001 Mammary gland involution is delayed by activated Akt in transgenic mice. Journal of Molecular Endocrinology 15 867-881.
43. Schwertfeger KL, McManaman JL, Palmer CA, Neville MC & Anderson SM 2003 Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation. Journal of Lipid Research 44 1100-1112.
44. Serri O, Chik CL, Ur E & Ezzat S 2003 Diagnosis and management of hyperprolactinemia. Canadian Medical Association Journal 169 575-581.
45. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F et al. 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. Journal of Clinical Endocrinology and Metabolism 83 667-674.
46. Tworoger SS, Eliassen AH, Rosner B, Sluss P & Hankinson SE 2004 Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Research 64 6814-6819.
47. Vomachka AJ, Pratt SL, Lockefeer JA & Horseman ND 2000 Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19 1077-1084.
48. Vonderhaar BK 1998 Prolactin: the forgotten hormone of human breast cancer. Pharmacology and Therapeutics 79 169-178.
49. Vonderhaar BK 1999 Prolactin involvement in breast cancer. Endocrine-Related Cancer 6 389-404.
50. Welsch CW & Nagasawa H 1977 Prolactin and murine mammary tumorigenesis: a review. Cancer Research 37 951-963.
51. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG & Tornell J 1997 Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. Journal of Clinical Investigation 100 2744-2751.
52. Zoubiane GS, Vilentijn A, Lowe ET, Akhtar N, Bagley S, Gilmore AP & Streuli CH 2004 A role for the cytoskeleton in prolactin-dependent mammary epithelial cell differentiation. Journal of Cell Science 117 271-280.